HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Switch Case Study: GSK Alli Review Shows FDA Data Mining In Context

This article was originally published in The Tan Sheet

Executive Summary

[F-D-C Reports' Pharmaceutical Approvals Monthly dissects drug reviews by FDA. While each drug stands or fails alone, a specific review can provide valuable insight into FDA's interpretation of data, policy and guidance documents, recurring controversies and resolution of internal disagreement. This story completes a two-part feature on alli.

You may also be interested in...

Sea Changes In Regulation And The Market: Top Stories Of 2008

When an iconic drug brand drew scrutiny on Capitol Hill for possibly violating FDA's policy against combinations of drugs and dietary supplements, OTC and supplement interests took notice

FDA “Safety First” Initiative, Agency’s Requests Draw Doubts From DeLauro

FDA is implementing the Safety First initiative to "ensure that significant post-market safety issues are our highest priority," according to acting Center for Drug Evaluation and Research Director Janet Woodcock

Alli Approved OTC For Weight Loss With “Goal Oriented” Indication

FDA's approved labeling for GlaxoSmithKline's first-in-class nonprescription weight-loss drug alli (orlistat 60 mg) emphasizes a "goal oriented" indication as opposed to a six-month duration of use as originally proposed

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts